Stimcell Energetics INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OQB
StimCell Energetics Inc. announced a new research collaboration to study its eBalance device's impact on neuronal mitochondrial function.
OQB
StimCell Energetics announces debt settlement via share issuance, a strategic partnership with Rain Communications for investor relations, and provides an update on the eBalance microcurrent therapy device redesign.
OQB
8-K: StimCell Energetics Partners with ADM Tronics to Redesign eBalance Microcurrent Device for Home Use
StimCell Energetics collaborates with ADM Tronics to create a smaller, more affordable eBalance microcurrent device for home use with advanced diagnostic features.
OQB
StimCell Energetics Inc. has partnered with Think Ink Marketing to enhance public awareness of the company and its products through a six-month marketing agreement.
OQB
StimCell Energetics Inc., formerly Cell MedX Corp., has completed a 1-for-15 reverse stock split and rebranded, aiming to redefine its strategic vision in cellular energetics.
OQB
Cell MedX Corp. has appointed new directors and increased its authorized share capital to 7.5 billion shares, effective April 1, 2024.
OQB
Cell MedX Corp. closed a private placement offering, raising $75,000 through the issuance of units, with a company director and spouse participating.
OQB
Cell MedX Corp. has announced the resignation of Brad Hargreaves from its Board of Directors, effective February 27, 2024.